Last reviewed · How we verify
NCT05554276: PD-1
Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer
Phase 2 trial testing neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy in Neoadjuvant Chemotherapy in 36 participants. Currently enrolling.
31 January 2025
Quick facts
| Lead sponsor | Shanghai Jiao Tong University Affiliated Sixth People's Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 1 August 2023 |
| Primary completion | 31 January 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
Conditions studied
- Neoadjuvant Chemotherapy — all drugs for Neoadjuvant Chemotherapy →
- PD-1 Antibody — all drugs for PD-1 Antibody →
- Radiotherapy — all drugs for Radiotherapy →
- Cervical Cancer — all drugs for Cervical Cancer →
Sponsor
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Who can join
Adults 18 to 70, female only, with Neoadjuvant Chemotherapy or PD-1 Antibody. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Based on various external factors and differences in the basic characteristics of patients, in my country, it is not clear whether concurrent chemoradiotherapy can achieve optimal therapeutic effect in patients with pathologically diagnosed stage IIB or above locally advanced cervical cancer. Under the limitations of radiotherapy and surgery conditions in the region, some patients will try neoadjuvant chemotherapy combined with PD-1 antibody therapy before standard radiotherapy, hoping to reduce cancer focus and reduce infiltration. Thereby reducing the scope of radiotherapy, better ensure the efficacy of late radiotherapy and chemotherapy and reduce the side effects of radiotherapy. Judging from the review of such patients, neoadjuvant chemotherapy combined with PD-1 antibody therapy + radical radiotherapy seems to have certain efficacy and tolerance in the near future as expected. No statistical analysis has been done on the long-term survival of patients. This topic intends to treat inoperable locally advanced cervical cancer patients with neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy, and explore the treatment-related toxic and side effects and efficacy of neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy. It is hoped that through this study, it will provide a reference for the comprehensive treatment of inoperable locally advanced cervical cancer that has been pathologically diagnosed in the future.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
Liu ZL, Chen HH, Zheng LL, Sun LP, et al · · 2023 · cited 808× · PMID 37169756 · DOI 10.1038/s41392-023-01460-1 -
Radiation-induced tumor immune microenvironments and potential targets for combination therapy.
Guo S, Yao Y, Tang Y, Xin Z, et al · · 2023 · cited 136× · PMID 37208386 · DOI 10.1038/s41392-023-01462-z -
Advances in cervical cancer: current insights and future directions.
Xu M, Cao C, Wu P, Huang X, et al · · 2025 · cited 55× · PMID 39611440 · DOI 10.1002/cac2.12629
Verify or expand the search:
- PubMed search for NCT05554276
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neoadjuvant Chemotherapy
Currently open trials in the same condition.
- NCT06998758 — Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC · Phase 3 · recruiting
- NCT06978322 — Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Canc · recruiting
- NCT06220214 — Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer · EARLY_PHASE1 · recruiting
- NCT07051083 — Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning · recruiting
- NCT06281210 — Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery · NA · recruiting
Other Shanghai Jiao Tong University Affiliated Sixth People's Hospital trials
Trials by the same sponsor.
- NCT07382063 — Effects of Extra-fascial Interscalene Brachial Plexus Block on Diaphragmatic Function in School-Aged Children · NA · enrolling by invitation
- NCT07278232 — Research on a Machine Learning-Based Predictive Model for Difficult Intubation Using Specific Vocal Characteristics · not yet recruiting
- NCT07171502 — AI-Assisted Ultrasound-Guided Nerve Block: Model Development and Performance Assessment · NA · completed
- NCT07133451 — Multimodal Imaging Evaluation of Vulnerability of Atherosclerotic Plaques: A Comparison of HR-VWI, OCT, and RWS · not yet recruiting
- NCT07125339 — High-resolution Magnetic Resonance Vessel Wall Imaging of Plaques · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05554276 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University Affiliated Sixth People's Hospital
- Last refreshed: 25 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05554276.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing